IP Library Patent Application 16349190
Patent Application
App. No. 16/349,190

PROBE DETECTION OF LOOP-MEDIATED AMPLIFICATION PRODUCTS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/349,190
Abstract

Disclosed herein are methods and compositions for detecting amplicon generated using loop-mediated amplification (LAMP). In particular, the invention relates to compositions comprising molecular beacons and/or LAMP primers and methods for generating and detecting LAMP amplicons. In particular, molecular beacons that bind to novel regions of a LAMP amplicon, and methods of using these probes, are provided.

Claims (37)

1 . A composition comprising a LAMP primer set and an oligonucleotide probe comprising a detectable label,

wherein said LAMP primer set, when used in a LAMP amplification reaction in the presence of a target nucleic acid, generates an amplicon comprising a first region or a second region, wherein the first region comprises a B1 region and an F1c region and extends from the 5′ end of the B1 region to the 3′ end of the F1c region, and wherein the second region comprises an F1 region and a B1c region and extends from the 5′ end of the F1 region to the 3′ end of the B1c region, and wherein the amplicon further comprises a probe target sequence; and

wherein the oligonucleotide probe binds specifically to said amplicon at the probe target sequence, wherein the probe target sequence overlaps with the first region or the second region.

2 . The composition of claim 1 , wherein the target nucleic acid comprises a B2 and a B1 region in this order from a 5′ terminal side, and an F2c and an F1c region in this order from a 3′ terminal side.

3 . The composition of claim 2 , wherein the LAMP primer set comprises:

a forward inner primer comprising an F1c region and an F2 region, wherein said F1c region of the forward inner primer comprises a sequence substantially identical to the F1c region of said target nucleic acid and wherein said F2 region of the forward inner primer comprises a sequence substantially complementary to the F2c region of the target nucleic acid; and

a backward inner primer comprising a B1c region and a B2 region, wherein said B1c region of the backward inner primer comprises a sequence substantially complementary to a B1 region of the target nucleic acid and wherein said B2 region of the backward inner primer comprises a sequence substantially identical to the B2 region of the target nucleic acid sequence.

4 . The composition of claim 3 , wherein said target nucleic acid further comprises an F3c region 3′ of said F2c region and a B3 region 5′ of said B2 region, and wherein said LAMP primer set further comprises a forward outer primer and a backward outer primer, wherein said forward outer primer comprises a sequence substantially complementary to the F3c region of the target nucleic acid and wherein said backward outer primer comprises a sequence substantially identical to the B3 region of the target nucleic acid.

5 . The composition of claim 3 , wherein said LAMP primer set further comprises a loop forward primer and a loop backward primer, wherein said loop forward primer comprises a sequence substantially identical to a sequence between said F1c and said F2c region of said target nucleic acid, and wherein said loop backward primer comprises a sequence substantially complementary to a sequence between said B1 and said B2 region of said target nucleic acid.

6 . The composition of claim 1 , wherein the oligonucleotide probe comprises a sequence substantially complementary to the probe target sequence.

7 . The composition of claim 1 , wherein the probe target sequence overlaps the first region or the second region of the amplicon by at least 3 nucleotides.

8 . The composition of claim 7 , wherein the probe target sequence overlaps the first region or the second region of the amplicon by at least 7 nucleotides.

9 . The composition of claim 8 , wherein the probe target sequence overlaps the first region or the second region of the amplicon by at least 10 nucleotides.

10 . The composition of claim 9 , wherein the probe target sequence is located completely within the first region or the second region of the amplicon.

11 . The composition of claim 1 , wherein the probe target sequence overlaps with at least 3 nucleotides, at least 7 nucleotides, at least 10 nucleotides, or all of the F1 region, the F1c region, the B1 region, or the B1c region of the amplicon.

12 . (canceled)

13 . (canceled)

14 . The composition of claim 1 , wherein said detectable label is a fluorophore.

15 . The composition of claim 1 , wherein said oligonucleotide probe further comprises a quencher.

16 . The composition of claim 15 , wherein said quencher is covalently bound to a terminus of the oligonucleotide probe.

17 .- 20 . (canceled)

21 . A method of detecting the presence or absence of a target nucleic acid in a test sample, the method comprising:

mixing the test sample with a reaction mixture comprising a strand displacement DNA polymerase and a LAMP primer set;

exposing said test sample to loop-mediated amplification reaction conditions to generate an amplicon from the target nucleic acid, if present in said test sample, wherein the amplicon comprises a probe target sequence;

contacting the test sample with an oligonucleotide probe comprising a detectable label, wherein the oligonucleotide probe binds specifically to the amplicon at the probe target sequence, if present, wherein the probe target sequence overlaps with a first region or a second region, wherein the first region comprises a B1 region and an F1c region and extends from the 5′ end of the B1 region to the 3′ end of the F1c region, and wherein the second region comprises an F1 region and a B1c region and extends from the 5′ end of the F1 region to the 3′ end of the B1c region; and

detecting the presence or absence of a signal from the detectable label, wherein the presence of said signal is indicative of the presence of the target nucleic acid in the test sample.

22 . The method of claim 21 , wherein said loop-mediated amplification reaction is performed at a temperature of between about 60° C. and about 67° C.

23 . The method of claim 22 , wherein said loop-mediated amplification reaction is performed for less than 30 minutes.

24 . The method of claim 23 , wherein said loop-mediated amplification reaction is performed for less than 15 minutes.

25 . (canceled)

26 . (canceled)

27 . The method claim 21 , wherein said reaction mixture further comprises a reverse transcriptase.

28 . A method of detecting the presence or absence of a target nucleic acid in a test sample, the method comprising:

providing a test sample suspected of comprising a target nucleic acid, wherein said test sample comprises the composition of claim 1 and a strand displacement DNA polymerase;

exposing said test sample to conditions sufficient to generate an amplicon from the target nucleic acid, if present in said test sample, via a loop-mediated amplification reaction; and

detecting the presence or absence of a signal from the detectable label, wherein the presence of said signal is indicative of the presence of the target nucleic acid in the test sample.

29 . (canceled)

Assignments (7)
CORRECTIVE ASSIGNMENT TO CORRECT THE THE STATE/COUNTRY ON THE COVER SHEET PREVIOUSLY RECORDED AT REEL: 66986 FRAME: 149. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Apr 11, 2024
From: TALIS BIOMEDICAL CORPORATION
To: TALIS BIOMEDICAL CORPORATION
Reel/Frame 067097/0916 →
CHANGE OF ADDRESS FROM 3400 BRIDGE PARKWAY, REDWOOD CITY TO 1100 ISLAND DRIVE, SUITE 101, REDWOOD CITY. Recorded Apr 2, 2024
From: TALIS BIOMEDICAL CORPORATION
To: TALIS BIOMEDICAL CORPORATION
Reel/Frame 066986/0144 →
CHANGE OF ADDRESS FROM 1100 ISLAND DRIVE, SUITE 101, REDWOOD CITY TO 1375 WEST FULTON MARKET, SUITE 700, CHICAGO. Recorded Apr 2, 2024
From: TALIS BIOMEDICAL CORPORATION
To: TALIS BIOMEDICAL CORPORATION
Reel/Frame 066986/0149 →
CHANGE OF ADDRESS FROM 230 CONSTITUTION DRIVE, MENLO PARK TO 3400 BRIDGE PARKWAY, REDWOOD CITY. Recorded Mar 27, 2024
From: TALIS BIOMEDICAL CORPORATION
To: TALIS BIOMEDICAL CORPORATION
Reel/Frame 066926/0028 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2021
From: DEDENT, ANDREA C.; LEE, MATTHEW B.; MAAMAR, HEDIA
To: SLIPCHIP CORPORATION
Reel/Frame 055229/0528 →
CHANGE OF NAME Recorded Feb 11, 2021
From: SLIPCHIP CORPORATION
To: TALIS BIOMEDICAL, INC.
Reel/Frame 055279/0764 →
CHANGE OF NAME Recorded Feb 11, 2021
From: TALIS BIOMEDICAL, INC.
To: TALIS BIOMEDICAL CORPORATION
Reel/Frame 055279/0786 →